PDMR Notification RSU Vesting

PureTech Health PLC

17 July 2026

 

17 July 2026

PureTech Health plc

PDMR Notifications

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company") a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announces that awards of restricted share units ("RSUs") granted by PureTech on 26 June 2024 to certain directors and other persons discharging managerial responsibilities ("PDMRs") pursuant to its Performance Share Plan ("PSP") 33% of the shares vested on 26 June 2026 and were subsequently issued to the PDMRs noted below.

Each PDMR received vested ordinary shares (after deduction of shares for payroll taxes) on 14 July 2026. The market price per ordinary share in the Company used to calculate the amount payable to the PDMRs and the amount of shares to be issued to PDMRs was 119.20 pence, being the average closing price of the Company's shares over the three-trading day period immediately prior to issuance, and the exchange rate used to calculate the cash payment and amount of share settlement was £1: $1.34.

The Company's total issued ordinary share capital is 257,927,489 shares after the share issuance to the PDMRs, 14,030,193 shares of which are held in treasury by the Company.

PDMR Notification

The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Eric Elenko Michael Inbar Charles Sherwood
2	Reason for the notification
a)	Position/status	Eric Elenko - President Michael Inbar - Chief Accounting Officer Charles Sherwood - Chief Operating Officer, General Counsel and Corporate Secretary
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	PureTech Health plc
b)	LEI	213800LVPDNO2Z9T9I39
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of PureTech Health plc ISIN GB00BY2Z0H74
b)	Nature of the transaction	Issuance of ordinary shares in net settlement of certain vested RSUs under the PureTech Health Performance Share Plan, after retentions in respect of payroll taxes.
c)	Price(s) and volume(s)	Recipient Price Amount Eric Elenko 0.01 GBP 56,735 ordinary shares Michael Inbar 0.01 GBP 30,245 ordinary shares Charles Sherwood 0.01 GBP 37,001 ordinary shares
d)	Aggregated information - Aggregated volume - Price	Price Aggregate Volume 0.01 GBP 123,981 ordinary shares
e)	Date of the transaction	14 July 2026
f)	Place of the transaction	London Stock Exchange (XLON)

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

For more information, visit www.puretechhealth.com or connect with us on LinkedIn and X (formerly Twitter) @puretechh. 

Contact:

PureTech

Investor Relations

[e-mail]

 

END